Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03789916
PHASE3

SAPT Versus DAPT in Incomplete Revascularization After CABG

Sponsor: Campus Bio-Medico University

View on ClinicalTrials.gov

Summary

The study aims to compare the efficacy of dual antiplatelet therapy (DAPT) over single antiplatelet therapy (SAPT) in patients with incomplete revascularization after coronary artery bypass graft surgery (CABG). Before hospital discharge, patients will be 1:1 randomized to SAPT (acetylsalicylic acid 100 mg/die) or DAPT (acetylsalicylic acid 100 mg/die + ticagrelor 90 mg bis in die). DAPT will be continued for 12 months, and ticagrelor will be withdrawn thereafter. Primary endpoint is the evaluation of cardiac-related mortality at 5 years from hospital discharge.

Official title: Single Versus Dual Antiplatelet Therapy in Patients With Incomplete Revascularization After Coronary Artery Bypass Graft Surgery

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

800

Start Date

2019-01-02

Completion Date

2026-12-31

Last Updated

2022-07-21

Healthy Volunteers

No

Interventions

DRUG

Ticagrelor

90 mg bis in die

DRUG

acetylsalicylic acid

100 mg die

Locations (1)

Università Campus Bio-Medico di Roma

Rome, Italy